| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT05669664 Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary… |
date change Primary completion moved earlier: 2027-04-11 -> 2026-11-30 |
| 2026-06-12 | NCT05669664 Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary… |
date change Completion moved earlier: 2027-04-11 -> 2026-11-30 |
| 2026-06-10 | NCT06592924 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration… |
Trial sites expanded: 340 -> 368 locations |
| 2026-06-04 | NCT03419234 Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone… |
date change Completion pushed: 2026-04-01 -> 2028-04-01 |
| 2026-05-28 | NCT04126070 Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors |
Primary endpoint(s) modified |
| 2026-05-28 | NCT04126070 Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors |
Enrollment reduced: 60 -> 47 participants |
| 2026-05-28 | NCT05849298 A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With… |
Trial sites reduced: 41 -> 37 locations |
| 2026-05-16 | NCT06305598 Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for… |
date change Primary completion pushed: 2026-12-15 -> 2029-12-15 |
| 2026-05-16 | NCT06305598 Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for… |
date change Completion pushed: 2027-12-15 -> 2029-12-15 |
| 2026-05-16 | NCT04423211 Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted… |
Trial sites expanded: 303 -> 342 locations |
| 2026-05-14 | NCT07450599 A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy… |
Recruitment opened |
| 2026-05-14 | NCT07455903 Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients… |
Recruitment opened |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-29 | NCT07613151 Negative Hormone Receptor and APOcrine Lobular Invasive Breast Cancer | Recruiting | |
| 2026-05-18 | NCT07593079 Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05717166 | A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up… | Metastatic Tumor | Recruiting |
| NCT06205316 | SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic… | Biochemically Recurrent Prostate Carcinoma | Recruiting |
| NCT07019363 | CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk… | Breast Cancer | Recruiting |
| NCT06650579 | REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial | Recurrent Prostate Carcinoma | Recruiting |
| NCT06235697 | Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment | Prostate Cancer | Recruiting |
| NCT04852887 | De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype… | Stage I Breast Cancer | Recruiting |
| NCT04916613 | ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable… | Prostate Cancer Metastatic | Recruiting |
| NCT04134260 | Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation… | Prostate Adenocarcinoma | Recruiting |
| NCT04423211 | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted… | Biochemically Recurrent Prostate Carcinoma | Recruiting |
| NCT06952803 | A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT… | Prostate Cancer | Recruiting |
| NCT06274047 | PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and… | Androgen Axis Suppression | Recruiting |
| NCT06592924 | Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration… | Prostate Cancer (Adenocarcinoma) | Recruiting |
| NCT04584853 | PreOperative Endocrine Therapy for Individualised Care With Abemaciclib | Breast Cancer Female | Active, Not Recruiting |
| NCT04455750 | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With… | Castration-Resistant Prostate Carcinoma | Active, Not Recruiting |
| NCT01674140 | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | Breast Cancer | Active, Not Recruiting |
| NCT07015268 | A Clinical Study of KLH-2109 in Patients With Endometriosis | Endometriosis | Active, Not Recruiting |
| NCT04076059 | An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT)… | Metastatic Hormone Sensitive Prostate Cancer | Active, Not Recruiting |
| NCT04513717 | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment… | Prostate Adenocarcinoma | Active, Not Recruiting |
| NCT05050084 | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less… | Prostate Adenocarcinoma | Active, Not Recruiting |
| NCT04484818 | Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy… | Prostate Carcinoma | Active, Not Recruiting |
| NCT01368588 | Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate… | Prostate Cancer | Active, Not Recruiting |
| NCT07477626 | Radiotherapy After Prostatectomy for Node Positive Prostate Cancer | Prostate Cancer (Post Prostatectomy) | Active, Not Recruiting |
| NCT07578116 | Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That… | Anatomic Stage IV Breast Cancer AJCC v8 | Not Yet Recruiting |
| NCT02489318 | A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT)… | Prostate Cancer | Active, Not Recruiting |
| NCT02531516 | An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer… | Prostatic Neoplasms | Active, Not Recruiting |